LexDanaLexDanabeta
Inventor

Kathrin Ute Jansen

Inventor
New York, NY, US

Overview

60→
Patents
1998–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 60 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes26%
C07KPeptides24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
C12NMicroorganisms or enzymes19%
Y02ATechnologies for adaptation to climate change4%
C12RIndexing scheme associated with subclasses c12c - c12q, relating to microorganisms2%
C08BPolysaccharides2%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
A61JContainers specially adapted for medical or pharmaceutical purposes1%
A61MDevices for introducing media into, or onto, the body0%
PatentTitleYear
11,090,375Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof202111,077,180Non-lipidated variants of 202110,982,198Compositions and methods relating to a mutant 202110,946,086Group B 202110,899,802None202110,888,611None202110,829,521None202010,813,989None202010,787,652Compositions and methods relating to a mutant clostridium difficile toxin202010,774,117Compositions relating to a mutant 202010,653,764Immunogenic compositions for use in pneumococcal vaccines202010,597,428Compositions relating to a mutant clostridium difficile toxin and methods thereof202010,550,159None202010,543,267None202010,512,681Non-lipidated variants of 201910,226,525Group B 201910,196,429None201910,183,070None20199,822,150'Neisseria meningitidis compositions and methods thereof'20179,802,987'Immunogenic fusion polypeptides'20179,757,443'Non-lipidated variants of Neisseria meningitidis ORF2086 antigens'20179,745,354'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'2017RE046518'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'20179,724,402'Neisseria meningitidis composition and methods thereof'2017RE046376'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'20179,623,100'Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions'20179,561,269'Neisseria meningitidis compositions and methods thereof'20179,492,559'Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof'20169,187,536'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'20159,125,951'Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions'20159,114,105'Immunogenic compositions of Staphylococcus aureus antigens'20158,986,710'Neisseria meningitidis compositions and methods thereof'20158,900,597'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'20148,889,145'Immunogenic compositions of Staphylococcus aureus antigens'20148,568,735'Immunogenic compositions of Staphylococcus aureus antigens'20138,557,548'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'20138,481,692'Compositions relating to a mutant Clostridium difficile toxin and methods thereof'20138,026,082'Synthetic gene control region'20117,976,848'Optimized expression of HPV 58 L1 in yeast'20117,744,892'Optimized expression of HPV 52 L1 in yeast'20107,700,103'Optimized expression of HPV 52 L1 in yeast'20107,498,036'Optimized expression of HPV 58 L1 in yeast'20097,482,428'Optimized expression of HPV 31 L1 in yeast'20097,482,015'Optimized expression of HPV 45 L1 in yeast'20097,276,243'Optimized expression of HPV31 L1 in yeast'20077,250,170'Optimized expression of HPV 45 L1 in yeast'20077,211,569'Synthetic human papilloma virus genes'20077,157,443'Staphylococcus aureus exopolysaccharide and process'20077,033,797'Synthetic virus-like particles with heterologous epitopes'20067,001,995'Synthetic human papillomavirus genes'20066,991,795'Protein delivery system using human papillomavirus virus-like particles'20066,908,615'DNA encoding human papilloma virus type 18'20056,841,157'Production of chimeric human papillomavirus'20056,689,366'Synthetic virus like particles with heterologous epitopes'20046,290,965'DNA encoding human papillomavirus type 6A'20016,159,729'Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein'20005,888,516'Recombinant papillomavirus vaccines'19995,840,306'DNA encoding human papillomavirus type 18'19985,820,870'Recombinant human papillomavirus type 18 vaccine'19985,821,087'Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–2010Patents assigned to MERCK & CO INC (18)· patent assignee history
1998–2005Based in Fort Washington, PA, US· patent location history
2004–2011Based in Doylestown, PA, US· patent location history
2007–2017Based in Allendale, NJ, US· patent location history
2010–2011Patents assigned to MERCK SHARP & DOHME (3)· patent assignee history
2010Based in South San Francisco, CA, US· patent location history
2013–2021Patents assigned to WYETH LLC (17)· patent assignee history
2013–2017Patents assigned to JANSEN KATHRIN UTE (4)· patent assignee history
2014–2021Based in New York, NY, US· patent location history
2015–2021Patents assigned to PFIZER (20)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
PFIZER202015–2021
MERCK & CO INC181998–2010
WYETH LLC172013–2021
JANSEN KATHRIN UTEself42013–2017
MERCK SHARP & DOHME32010–2011
Locations
LocationPatentsSpan
New York, New York, US262014–2021
Allendale, New Jersey, US142007–2017
Doylestown, Pennsylvania, US112004–2011
Fort Washington, Pennsylvania, US71998–2005
South San Francisco, California, US22010